Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

B. Venugopal · SciRah

Researcher profile · Semantic Scholar

B. Venugopal

Share profile

B. Venugopal — researcher profile on SciRah

h-index: 19
Works: 90
Citations: 5,088

Most-cited papers

Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
R. Motzer, K. Penkov, J. Haanen, B. Rini +24 more
2019New England Journal of Medicine2,071 citations Open access
Semantic Scholar
Gold Nanoparticles for the Improved Anticancer Drug Delivery of the Active Component of Oxaliplatin
S. D. Brown, P. Nativo, Joanne F. Smith, David Stirling +6 more
2010Journal of the American Chemical Society792 citations Open access
Semantic Scholar
Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma.
T. Choueiri, P. Tomczak, S. Park, B. Venugopal +29 more
2021New England Journal of Medicine608 citations Open access
Semantic Scholar
Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma
T. Choueiri, R. Motzer, B. Rini, J. Haanen +21 more
2020Annals of Oncology401 citations Open access
Semantic Scholar
Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
T. Powles, P. Tomczak, S. Park, B. Venugopal +17 more
2022The Lancet Oncology229 citations Open access
Semantic Scholar
A Phase I Study of Quisinostat (JNJ-26481585), an Oral Hydroxamate Histone Deacetylase Inhibitor with Evidence of Target Modulation and Antitumor Activity, in Patients with Advanced Solid Tumors
B. Venugopal, R. Baird, R. Kristeleit, R. Plummer +13 more
2013Clinical Cancer Research116 citations Open access
Semantic Scholar
A phase I trial of the γ-secretase inhibitor MK-0752 in combination with gemcitabine in patients with pancreatic ductal adenocarcinoma
N. Cook, B. Basu, Donna M. Smith, A. Gopinathan +15 more
2018British Journal of Cancer99 citations Open access
Semantic Scholar
Cucurbit[7]uril encapsulated cisplatin overcomes cisplatin resistance via a pharmacokinetic effect.
J. Plumb, B. Venugopal, Rabbab Oun, N. Gomez-Roman +3 more
2012Metallomics99 citations Open access
Semantic Scholar
Developing histone deacetylase inhibitors as anti-cancer therapeutics.
B. Venugopal, T. Jeffry Evans
2011Current Medicinal Chemistry89 citations
Semantic Scholar
Efficacy and correlative analyses of avelumab plus axitinib versus sunitinib in sarcomatoid renal cell carcinoma: post hoc analysis of a randomized clinical trial
T. Choueiri, J. Larkin, S. Pal, R. Motzer +15 more
2021ESMO Open52 citations Open access
Semantic Scholar
Updated ef ﬁ cacy results from the JAVELIN Renal 101 trial: ﬁ rst-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma
T. Choueiri, R. Motzer, B. Rini, J. Haanen +21 more
202038 citations
Semantic Scholar
Efficacy and biomarker analysis of patients (pts) with advanced renal cell carcinoma (aRCC) with sarcomatoid histology (sRCC): Subgroup analysis from the phase III JAVELIN renal 101 trial of first-line avelumab plus axitinib (A + Ax) vs sunitinib (S)
T. Choueiri, J. Larkin, S. Pål, R. Motzer +12 more
2019Annals of Oncology37 citations Open access
Semantic Scholar
Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for patients with renal cell carcinoma: Randomized, double-blind, phase III KEYNOTE-564 study.
T. Choueiri, P. Tomczak, S. Park, B. Venugopal +16 more
2021Journal of Clinical Oncology35 citations
Semantic Scholar
Overall survival results from the phase 3 KEYNOTE-564 study of adjuvant pembrolizumab versus placebo for the treatment of clear cell renal cell carcinoma (ccRCC).
T. Choueiri, P. Tomczak, Se Hoon Park, B. Venugopal +16 more
2024Journal of Clinical Oncology25 citations
Semantic Scholar
Patient-Reported Outcomes in KEYNOTE-564: Adjuvant Pembrolizumab Versus Placebo for Renal Cell Carcinoma
T. Choueiri, P. Tomczak, S. Park, B. Venugopal +17 more
2023The Oncologist25 citations Open access
Semantic Scholar
An open-label study to describe pharmacokinetic parameters of erlotinib in patients with advanced solid tumors with adequate and moderately impaired hepatic function
C. O'Bryant, P. Haluska, L. Rosen, R. Ramanathan +9 more
2012Cancer Chemotherapy and Pharmacology24 citations
Semantic Scholar
Real‐world uptake, safety profile and outcomes of docetaxel in newly diagnosed metastatic prostate cancer
R. Rulach, S. Mckay, S. Neilson, Lillian White +15 more
2018BJU International23 citations Open access
Semantic Scholar
Pembrolizumab as post nephrectomy adjuvant therapy for patients with renal cell carcinoma: Results from 30-month follow-up of KEYNOTE-564.
T. Choueiri, P. Tomczak, S. Park, B. Venugopal +16 more
2022Journal of Clinical Oncology22 citations
Semantic Scholar
Efficacy of temsirolimus in metastatic chromophobe renal cell carcinoma
B. Venugopal, J. Ansari, M. Aitchison, L. Tho +2 more
2013BMC Urology20 citations Open access
Semantic Scholar
Avelumab + axitinib vs sunitinib in patients (pts) with advanced renal cell carcinoma (aRCC): Final overall survival (OS) analysis from the JAVELIN Renal 101 phase 3 trial.
R. Motzer, K. Penkov, H. Uemura, M. Campbell +16 more
2024Journal of Clinical Oncology18 citations
Semantic Scholar
CaboPoint: Interim results from a phase 2 study of cabozantinib after checkpoint inhibitor (CPI) therapy in patients with advanced renal cell carcinoma (RCC).
L. Albiges, T. Powles, Anand Sharma, B. Venugopal +6 more
2023Journal of Clinical Oncology18 citations
Semantic Scholar
Cardiotoxicity and myocardial hypoperfusion associated with anti‐vascular endothelial growth factor therapies: prospective cardiac magnetic resonance imaging in patients with cancer
Stephen J. H. Dobbin, K. Mangion, C. Berry, G. Roditi +8 more
2020European Journal of Heart Failure18 citations Open access
Semantic Scholar
A first-in-human phase I and pharmacokinetic study of CP-4126 (CO-101), a nucleoside analogue, in patients with advanced solid tumours
B. Venugopal, A. Awada, T. Jeffry Evans, S. Dueland +5 more
2015Cancer Chemotherapy and Pharmacology16 citations
Semantic Scholar
LBA02-09 EMBARK: A PHASE 3 RANDOMIZED STUDY OF ENZALUTAMIDE OR PLACEBO PLUS LEUPROLIDE ACETATE AND ENZALUTAMIDE MONOTHERAPY IN HIGH-RISK BIOCHEMICALLY RECURRENT PROSTATE CANCER
N. Shore, M. de Almeida Luz, U. de Giorgi, M. Gleave +14 more
2023Journal of Urology15 citations
Semantic Scholar
Evaluation of brain metastasis in JAVELIN Renal 101: Efficacy of avelumab + axitinib (A+Ax) versus sunitinib (S).
E. Jonasch, E. Hasanov, R. Motzer, S. Hariharan +14 more
202015 citations
Semantic Scholar
Standard Versus Modified Ipilimumab, in Combination With Nivolumab, in Advanced Renal Cell Carcinoma: A Randomized Phase II Trial (PRISM)
N. Vasudev, G. Ainsworth, S. Brown, Lisa M. Pickering +23 more
2023Journal of Clinical Oncology13 citations Open access
Semantic Scholar
The WIRE study a phase II, multi-arm, multi-centre, non-randomised window-of-opportunity clinical trial platform using a Bayesian adaptive design for proof-of-mechanism of novel treatment strategies in operable renal cell cancer – a study protocol
S. Ursprung, H. Mossop, F. Gallagher, E. Sala +20 more
2021BMC Cancer13 citations Open access
Semantic Scholar
A phase II trial of cemiplimab alone or in combination with standard of care chemotherapy in locally advanced or metastatic penile carcinoma (EPIC Trial).
E. Renninson, A. Challapalli, E. Foulstone, A. Bravo +11 more
2022Journal of Clinical Oncology12 citations Open access
Semantic Scholar
Belzutifan plus lenvatinib for patients (pts) with advanced clear cell renal cell carcinoma (ccRCC) after progression on a PD-1/L1 and VEGF inhibitor: Preliminary results of arm B5 of the phase 1/2 KEYMAKER-U03B study.
L. Albiges, K. Beckermann, Wilson H. Miller, Jeffrey C. Goh +15 more
2023Journal of Clinical Oncology11 citations Open access
Semantic Scholar
VinCaP: a phase II trial of vinflunine in locally advanced and metastatic squamous carcinoma of the penis
S. Nicholson, H. Tovey, T. Elliott, S. Burnett +13 more
2021British Journal of Cancer11 citations Open access
Semantic Scholar
A phase I trial of the ɣ-secretase inhibitor (GSI) MK-0752 in combination with gemcitabine in patients with pancreatic ductal adenocarcinoma (PDAC).
N. Cook, B. Basu, Donna M. Smith, A. Gopinathan +12 more
201410 citations
Semantic Scholar
Early Clinical Experience with Cabozantinib for Advanced Renal Cell Carcinoma in the UK: Real-World Treatment Pathways and Clinical Outcomes.
B. Venugopal, M. Pillai, T. Powles, P. Savage +5 more
2021Clinical Genitourinary Cancer9 citations Open access
Semantic Scholar
Belzutifan versus everolimus in participants (pts) with previously treated advanced renal cell carcinoma (RCC): Patient-reported outcomes (PROs) in the phase 3 LITESPARK-005 study.
T. Powles, L. Albiges, K. Jalkanen, G. de Velasco +16 more
2024Journal of Clinical Oncology7 citations
Semantic Scholar
Adjuvant pembrolizumab (pembro) for renal cell carcinoma (RCC) across UCLA Integrated Staging System (UISS) risk groups and disease stage: Subgroup analyses from the KEYNOTE-564 study.
T. Choueiri, P. Tomczak, S. Park, B. Venugopal +16 more
2023Journal of Clinical Oncology7 citations
Semantic Scholar
Cabozantinib in metastatic renal cell carcinoma (mRCC): Data from UK expanded access program (EAP).
A. Gomez de Liano Lista, B. Venugopal, K. Fife, S. Symeonides +9 more
2018Annals of Oncology7 citations Open access
Semantic Scholar
First-in-human study of a novel nucleoside analogue, CP-4126, in patients with advanced solid tumors.
B. Nilsson, Alain Hendlisz, M. Castellà, Steinar Aamdal +6 more
2016Journal of Clinical Oncology7 citations
Semantic Scholar
LBA29 Nivolumab in combination with alternatively scheduled ipilimumab in first-line treatment of patients with advanced renal cell carcinoma: A randomized phase II trial (PRISM)
N. Vasudev, G. Ainsworth, Sarah Brown, L. Pickering +16 more
2021Annals of Oncology6 citations Open access
Semantic Scholar
NAXIVA: A phase II neoadjuvant study of axitinib for reducing extent of venous tumor thrombus in clear cell renal cell cancer (RCC) with venous invasion.
G. Stewart, S. Welsh, S. Ursprung, F. Gallagher +16 more
20216 citations
Semantic Scholar
Cabozantinib in metastatic renal cell carcinoma (mRCC): Real world experience from the UK.
A. G. de Liaño, B. Venugopal, K. Fife, Luma Khasti +6 more
20185 citations
Semantic Scholar
Chemotherapy for bladder cancer: A United Kingdom practice survey
P. F. Egan, B. Venugopal, R. Jones
20085 citations
Semantic Scholar
Cabozantinib in the Routine Management of Renal Cell Carcinoma: A Systematic Literature Review of Real-World Evidence.
M. Gross-Goupil, Lubomir Bodnar, M. Campbell, A. Michael +5 more
2023Clinical Genitourinary Cancer4 citations Open access
Semantic Scholar
Resilience of hospital and allied infrastructure during pandemic and post pandemic periods for maternal health care of pregnant women and infants in Tamil Nadu, India ‐ A counterfactual analysis
Kandaswamy Paramasivan, Ashwin Prakash, Sarthak Gupta, Bhairav Phukan +2 more
2023PLoS ONE4 citations Open access
Semantic Scholar
Association of C-reactive protein (CRP) with efficacy of avelumab + axitinib (A + Ax) in advanced renal cell carcinoma (aRCC): Long-term follow-up results from JAVELIN Renal 101.
Y. Tomita, J. Larkin, B. Venugopal, J. Haanen +8 more
20214 citations
Semantic Scholar
653O Pembrolizumab (pembro) vs placebo as adjuvant therapy for patients (pts) with renal cell carcinoma (RCC): Patient-reported outcomes (PRO) in KEYNOTE-564
T. Choueiri, P. Tomczak, S. Park, B. Venugopal +16 more
2021Annals of Oncology4 citations Open access
Semantic Scholar
Prevalence of Ankyloglossia among Children Reporting with Speech Pathology to District Early Intervention Centre (DEIC)- An Observational Study
P. Chandrasekaran, Jaganbabu Palaniappan, Appadurai Rajendran, B. Venugopal +1 more
20204 citations
Semantic Scholar
Coexistent malignant melanoma and renal cell carcinoma.
B. Venugopal, T. R. Jeffry Evans
2009Tumori4 citations
Semantic Scholar
Baseline and Dynamic Changes in Hemoglobin Levels Predict Treatment Response and Prognosis in Metastatic Renal Cell Carcinoma: A Multicenter Retrospective Study.
Yu-Hsuen Yang, S. Ansel, Aafke Meerveld-Eggink, F. Jackson-Spence +12 more
2023Clinical Genitourinary Cancer3 citations Open access
Semantic Scholar
Influence of tumor size in the progression of venous tumor thrombus in renal cell carcinoma: A 7-year single-center experience
M. Thangarasu, J. S. Prakash, S. Bafna, P. Aarthy +12 more
2022Urology Annals3 citations Open access
Semantic Scholar
A phase I trial of the c-secretase inhibitor MK-0752 in combination with gemcitabine in patients with pancreatic ductal adenocarcinoma
N. Cook, B. Basu, Donna M. Smith, A. Gopinathan +15 more
20183 citations
Semantic Scholar
Late recurrences of renal cell carcinoma at unusual sites: implications for patient management.
B. Venugopal, T. R. Jeffry Evans
2012Clinical advances in hematology & oncology : H&O3 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

T. Powles×15
Invite
T. Powles — researcher profile on SciRah
T. Choueiri×11
Invite
T. Choueiri — researcher profile on SciRah
S. Symeonides×11
Invite
S. Symeonides — researcher profile on SciRah
L. Albiges×9
Invite
L. Albiges — researcher profile on SciRah

M. Gross-Goupil

×9

Invite

M. Gross-Goupil — researcher profile on SciRah

Invite

J. Hajek — researcher profile on SciRah

Invite

N. Sarwar — researcher profile on SciRah

Invite

M. Mahave — researcher profile on SciRah

Invite

P. Sawrycki — researcher profile on SciRah

Invite

P. Tomczak — researcher profile on SciRah

Invite

S. Park — researcher profile on SciRah

A. Thiery-Vuillemin×7

Invite

A. Thiery-Vuillemin — researcher profile on SciRah